USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Yes100% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$312 – $1329
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your latuda prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about lurasidone. Some of the dosage forms listed on this page may not apply to the brand name Latuda.
Common side effects of Latuda include: psychomotor impairment, akathisia, basal ganglia disease, bradykinesia, cogwheel rigidity, drowsiness, hypokinesia, muscle rigidity, nausea, parkinson's disease, sedated state, tremor, altered serum glucose, and drooling. Other side effects include: oculogyric crisis, trismus, agitation, anxiety, dystonia, torticollis, increased serum prolactin, and weight gain. See below for a comprehensive list of adverse effects.
Applies to lurasidone: oral tablet
Oral route (Tablet)
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone is not approved for the treatment of patients with dementia-related psychosis. An increased risk of suicidal thoughts and behavior was found in pediatric and young adult patients taking antidepressants. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors.
Along with its needed effects, lurasidone (the active ingredient contained in Latuda) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking lurasidone:
Incidence not known
Some side effects of lurasidone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to lurasidone: oral tablet
The most commonly reported adverse events included somnolence, akathisia, extrapyramidal symptoms, and nausea.
Common (1% to 10%): Decreased appetite, increased appetite, increased weight
Uncommon (0.1% to 1%): Hyponatremia, increase in blood sugar levels/blood glucose increased
In uncontrolled, long-term schizophrenia trials, this drug was associated with a mean increase in glucose from baseline of 1.8 mg/dL at 24 weeks, 0.8 mg/dL at 36 weeks, and 2.3 mg/dL at 52 weeks. Similar results were observed in bipolar depression studies. The proportion of patients with a 7% or greater increase in body weight was 4.8% (compared with 3.3% for placebo). Pooled data from short-term trials showed a mean weight gain of 0.43 kg in treated patients (compared with -0.2 kg in placebo).
Very common (10% or more): Nausea (up to 17.4%), dyspepsia (up to 11%)
Common (1% to 10%): Abdominal pain, diarrhea, dry mouth, salivary hypersecretion, stomach discomfort, upper abdominal pain, vomiting
Uncommon (0.1% to 1%): Dysphagia, flatulence, gastritis
Frequency not reported: Difficulty swallowing, tongue protrusion, tongue spasm, tongue swelling
Akathisia and extrapyramidal symptoms were dose-related.
Very common (10% or more): Somnolence (up to 26%), akathisia (up to 22%), extrapyramidal disorder/symptoms (up to 22%), parkinsonism (up to 17%)
Common (1% to 10%): Dizziness, dyskinesia, dystonia/acute dystonia, tardive dyskinesia
Uncommon (0.1% to 1%): Cerebrovascular accident/adverse reactions, dysarthria, gait disturbance, lethargy, syncope, vertigo
Rare (less than 0.1%): Neuroleptic malignant syndrome, seizure
Frequency not reported: Abnormal glabellar reflex, bradykinesia, cogwheel rigidity, convulsion, drooling, hyperkinesia, hypersomnia, hypersomnolence, hypokinesia, motor impairment, oromandibular dystonia, sedation, stroke, tremor
Very common (10% or more): Insomnia (up to 11%)
Common (1% to 10%): Abnormal dreams, agitation, anxiety, psychomotor hyperactivity, restlessness
Uncommon (0.1% to 1%): Activation of mania/hypomania, catatonia, nightmare, panic attack, sleep disorder
Rare (less than 0.1%): Suicidal behavior/ideation
Frequency not reported: Cognitive impairment, psychomotor retardation
Uncommon (0.1% to 1%): Anemia
Rare (less than 0.1%): Eosinophilia
Frequency not reported: Agranulocytosis, leukopenia, neutropenia
Common (1% to 10%): Hypertension, tachycardia
Uncommon (0.1% to 1%): Angina pectoris, atrioventricular (AV) block first degree, bradycardia, hot flush, hypotension, increased blood pressure, orthostatic hypotension
Frequency not reported: Deep vein thrombosis, venous thromboembolism
Common (1% to 10%): Back pain, increased blood creatinine phosphokinase, musculoskeletal stiffness
Uncommon (0.1% to 1%): Joint stiffness, myalgia, neck pain
Rare (less than 0.1%): Rhabdomyolysis
Frequency not reported: Muscle rigidity, muscle spasms, neck muscle spasm, torticollis, trismus
Common (1% to 10%): Rash, pruritus
Uncommon (0.1% to 1%): Hyperhidrosis
Frequency not reported: , Stevens-Johnson syndrome, urticaria
Postmarketing reports: Bullous dermatitis, maculopapular rash, pustular rash, severe cutaneous reactions, skin eruption, skin exfoliation
Common (1% to 10%): Urinary tract infection
Uncommon (0.1% to 1%): Amenorrhea, dysmenorrhea, dysuria, erectile dysfunction
Rare (less than 0.1%): Breast enlargement, breast pain, galactorrhea
Common (1% to 10%): Elevated serum creatinine/increased creatinine phosphokinase
Rare (less than 0.1%): Renal failure
Uncommon (0.1% to 1%): Elevated prolactin levels/blood prolactin increased
Frequency not reported: Hyperprolactinemia
Uncommon (0.1% to 1%): Alanine aminotransferase increased
Common (1% to 10%): Hypersensitivity
Rare (less than 0.1%): Angioedema
Frequency not reported: Allergic rhinitis
Very common (10% or more): Viral infection (up to 11%)
Common (1% to 10%): Influenza
Common (1% to 10%): Blurred vision
Frequency not reported: Oculogyric crisis
Common (1% to 10%): Fatigue
Rare (less than 0.1%): Sudden death
Frequency not reported: Body temperature dysregulation, falls, neonatal drug withdrawal syndrome
Common (1% to 10%): Nasopharyngitis, oropharyngeal pain, rhinitis
Frequency not reported: Difficulty breathing, nasal congestion, rhinorrhea, pulmonary embolism, throat tightness, upper respiratory tract infection
Postmarketing reports: Dyspnea, throat swelling
June 26, 2020
June 25, 2020
June 27, 2020
July 10, 2020
July 9, 2020
July 1, 2020